Tracon inks deal with Ambrx to develop cancer drug in China; Roche wins consecutive approvals in EU and US
→ Two San Diego companies have inked a licensing deal to develop a cancer drug in China and Taiwan. Ambrx gets exclusive rights to develop …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
